const g=(e="")=>e==="prevalence"?i():e==="pathophysiology"?t():e==="pathogenesis"?n():e==="causes"?a():e==="pathology"?o():e==="classification"?s():e==="clinical-presentation"?r():e==="examination-findings"?l():e==="investigations"?c():e==="diagnosis"?m():e==="management"?p():e==="prognosis-outcomes"?u():e==="kenya-context"?d():[{title:"Wernicke's Encephalopathy in Pregnancy - Comprehensive Management",clickableItems:[{text:"ğŸ“Š Prevalence & Epidemiology",sectionId:"prevalence"},{text:"âš¡ Pathophysiology",sectionId:"pathophysiology"},{text:"ğŸ§¬ Pathogenesis",sectionId:"pathogenesis"},{text:"ğŸ” Causes & Risk Factors",sectionId:"causes"},{text:"ğŸ”¬ Pathology & Neuropathology",sectionId:"pathology"},{text:"ğŸ“‹ Classification & Types",sectionId:"classification"},{text:"ğŸ©º Clinical Presentation",sectionId:"clinical-presentation"},{text:"ğŸ‘©â€âš•ï¸ Examination Findings",sectionId:"examination-findings"},{text:"ğŸ” Investigations",sectionId:"investigations"},{text:"ğŸ¯ Diagnosis",sectionId:"diagnosis"},{text:"ğŸ’Š Management & Treatment",sectionId:"management"},{text:"ğŸ“ˆ Prognosis & Outcomes",sectionId:"prognosis-outcomes"},{text:"ğŸ‡°ğŸ‡ª Kenya-Specific Considerations",sectionId:"kenya-context"}]},{title:"Wernicke's Encephalopathy in Pregnancy Overview",points:["ğŸ§  **Definition**: Acute neuropsychiatric syndrome due to thiamine (B1) deficiency","ğŸ“Š **Prevalence**: Rare but underdiagnosed, 0.01-0.1% of pregnancies","ğŸ¤¢ **Association**: Strongly linked with hyperemesis gravidarum","ğŸ”º **Classic Triad**: Confusion, ataxia, ophthalmoplegia (only 16% have all three)","âš¡ **Emergency**: Medical emergency requiring immediate thiamine replacement","ğŸ§¬ **Reversibility**: Early treatment prevents permanent neurological damage","ğŸ’€ **Mortality**: 10-20% if untreated, <5% with prompt treatment"]},{title:"Key Clinical Features",subsections:[{title:"Classic Triad (Rare Complete Presentation)",points:["ğŸ§  **Confusion**: Altered mental status, disorientation","ğŸš¶ **Ataxia**: Gait disturbance, incoordination","ğŸ‘ï¸ **Ophthalmoplegia**: Eye movement abnormalities","ğŸ“Š **Complete Triad**: Present in only 16% of cases"]},{title:"Common Pregnancy Presentations",points:["ğŸ¤¢ **Hyperemesis Gravidarum**: Severe nausea and vomiting","ğŸ˜µ **Altered Mental Status**: Confusion, apathy, memory loss","ğŸ‘ï¸ **Visual Disturbances**: Diplopia, nystagmus","ğŸš¶ **Balance Problems**: Ataxia, unsteady gait"]},{title:"Emergency Recognition",points:["ğŸš¨ **High Index of Suspicion**: Any neurological symptoms with poor nutrition","âš¡ **Rapid Progression**: Can progress to coma within hours","ğŸ’‰ **Immediate Treatment**: Thiamine before glucose administration","ğŸ¥ **Hospitalization**: Usually requires inpatient management"]}]}],i=()=>[{title:"Prevalence and Epidemiology of Wernicke's Encephalopathy in Pregnancy",subsections:[{title:"Overall Prevalence",points:["ğŸ“Š **General Population**: 0.01-0.1% of all pregnancies","ğŸ¥ **Hospital Reports**: Case reports and small series","ğŸ¤¢ **Hyperemesis Association**: 0.1-1% of severe hyperemesis cases","ğŸŒ **Geographic Variation**: Higher in areas with poor nutrition","ğŸ“ˆ **Underdiagnosis**: Likely significantly underreported","â° **Timing**: Most common in first trimester"]},{title:"Risk Factor Epidemiology",points:["ğŸ¤¢ **Hyperemesis Gravidarum**: 80-90% of pregnancy cases","ğŸ‘© **Maternal Age**: No specific age predilection","ğŸ½ï¸ **Nutritional Status**: Malnutrition, eating disorders","ğŸ· **Alcohol Use**: Pre-pregnancy alcohol dependence","ğŸ’Š **Medication Use**: Diuretics, antiemetics","ğŸ§¬ **Genetic Factors**: Possible genetic predisposition"]},{title:"Gestational Timing",points:["ğŸ¥‡ **First Trimester**: 70-80% of cases","ğŸ¥ˆ **Second Trimester**: 15-20% of cases","ğŸ¥‰ **Third Trimester**: 5-10% of cases","ğŸ¤± **Postpartum**: Rare, usually related to continued poor nutrition","â° **Duration**: Usually after 2-4 weeks of poor intake","ğŸ“… **Peak**: 6-12 weeks gestation"]},{title:"Associated Conditions",points:["ğŸ¤¢ **Hyperemesis Gravidarum**: Primary association","ğŸ½ï¸ **Eating Disorders**: Anorexia nervosa, bulimia","ğŸ§  **Psychiatric Disorders**: Depression, anxiety","ğŸ’Š **Substance Use**: Alcohol, drug abuse","âš•ï¸ **Medical Conditions**: Thyroid disease, diabetes","ğŸ¥ **Hospitalization**: Often requires admission"]},{title:"Outcome Statistics",points:["ğŸ’€ **Mortality**: 10-20% if untreated","ğŸ§  **Permanent Disability**: 30-50% without early treatment","ğŸ”„ **Recovery**: 70-90% with prompt thiamine therapy","ğŸ‘¶ **Fetal Outcomes**: Variable, depends on maternal status","âš¡ **Early Treatment**: <24 hours crucial for good outcomes","ğŸ“Š **Long-term**: Most recover with appropriate treatment"]},{title:"Diagnostic Challenges",points:["ğŸ” **Underrecognition**: Often missed or misdiagnosed","ğŸ“Š **Nonspecific Symptoms**: Overlap with pregnancy symptoms","â° **Late Diagnosis**: Often diagnosed post-mortem","ğŸ§ª **Laboratory**: Normal thiamine levels don't exclude diagnosis","ğŸ§  **Clinical**: Requires high index of suspicion","ğŸ“š **Education**: Need for increased awareness"]}]}],t=()=>[{title:"Pathophysiology of Wernicke's Encephalopathy in Pregnancy",subsections:[{title:"Thiamine Metabolism",points:["ğŸ§¬ **Thiamine Function**: Essential coenzyme in glucose metabolism","âš¡ **Energy Production**: Required for ATP synthesis","ğŸ”„ **Enzyme Systems**: Pyruvate dehydrogenase, Î±-ketoglutarate dehydrogenase","ğŸ§  **Brain Dependence**: Brain highly dependent on glucose metabolism","ğŸ’§ **Water-Soluble**: Not stored in body, requires daily intake","ğŸ“‰ **Depletion**: Stores depleted within 2-3 weeks"]},{title:"Cellular Energy Failure",points:["âš¡ **ATP Depletion**: Reduced energy production","ğŸ”„ **Lactate Accumulation**: Anaerobic metabolism","ğŸ’« **Oxidative Stress**: Free radical formation","ğŸ§¬ **DNA Damage**: Cellular damage from ROS","ğŸ’€ **Cell Death**: Neuronal death in vulnerable regions","ğŸ”¥ **Inflammation**: Secondary inflammatory response"]},{title:"Neurotransmitter Systems",points:["ğŸ§  **Acetylcholine**: Reduced synthesis and release","âš¡ **GABA**: Altered GABAergic neurotransmission","ğŸ’« **Glutamate**: Excitotoxicity from glutamate","ğŸ”„ **Dopamine**: Altered dopaminergic function","ğŸŒŠ **Serotonin**: Changes in serotonergic pathways","ğŸ§¬ **Norepinephrine**: Affected noradrenergic systems"]},{title:"Vascular Changes",points:["ğŸ©¸ **Blood-Brain Barrier**: Increased permeability","ğŸ’§ **Edema**: Vasogenic and cytotoxic edema","âš¡ **Microhemorrhages**: Petechial hemorrhages","ğŸ”„ **Hypoperfusion**: Reduced cerebral blood flow","ğŸ’« **Vasodilation**: Compensatory vessel dilation","ğŸŒŠ **Endothelial Dysfunction**: Vascular integrity loss"]},{title:"Pregnancy-Specific Factors",points:["ğŸ¤¢ **Hyperemesis**: Severe vomiting depletes stores","ğŸ§¬ **Increased Demands**: Higher thiamine requirements","ğŸ’§ **Hemodilution**: Dilutional effects","âš¡ **Hormonal Changes**: Affect thiamine metabolism","ğŸ”„ **Placental Transfer**: Fetal thiamine demands","ğŸŒŠ **Nausea/Vomiting**: Impaired oral intake"]},{title:"Regional Brain Vulnerability",points:["ğŸ§  **Thalamus**: High metabolic rate region","ğŸ’« **Mammillary Bodies**: Vulnerable to thiamine deficiency","âš¡ **Brainstem**: Critical for vital functions","ğŸ”„ **Hypothalamus**: Regulatory center involvement","ğŸŒŠ **Periaqueductal Gray**: Pain and consciousness","ğŸ¯ **Selective Vulnerability**: Specific neuronal populations"]}]}],n=()=>[{title:"Pathogenesis of Wernicke's Encephalopathy in Pregnancy",subsections:[{title:"Thiamine Deficiency Development",points:["ğŸ½ï¸ **Reduced Intake**: Poor oral intake due to nausea/vomiting","ğŸ¤¢ **Malabsorption**: Impaired GI absorption","ğŸ’§ **Increased Losses**: Losses through vomiting","âš¡ **Increased Demands**: Higher metabolic requirements","ğŸ”„ **Store Depletion**: Rapid depletion of body stores","ğŸ§¬ **Genetic Factors**: Polymorphisms affecting metabolism"]},{title:"Hyperemesis Gravidarum Pathway",points:["ğŸ¤¢ **Severe Vomiting**: Primary mechanism","ğŸ’§ **Dehydration**: Fluid and electrolyte losses","ğŸ½ï¸ **Nutritional Depletion**: Multiple vitamin deficiencies","âš¡ **Ketosis**: Metabolic complications","ğŸ”„ **Cycle Perpetuation**: Worsening nutritional status","ğŸ§  **CNS Effects**: Direct neurological impact"]},{title:"Metabolic Cascade",points:["ğŸ§¬ **Enzyme Deficiency**: Reduced transketolase activity","âš¡ **Glucose Metabolism**: Impaired glucose utilization","ğŸ’« **Pentose Phosphate**: Disrupted pathway","ğŸ”„ **Energy Crisis**: Cellular ATP depletion","ğŸŒŠ **Lactate Production**: Shift to anaerobic metabolism","ğŸ¯ **Neuronal Death**: Progressive cell death"]},{title:"Anatomical Progression",points:["ğŸ§  **Initial Sites**: Mammillary bodies, thalamus","âš¡ **Progression**: Brainstem, hypothalamus","ğŸ’« **Symmetrical**: Bilateral symmetrical lesions","ğŸ”„ **Selective**: Specific neuroanatomical vulnerability","ğŸŒŠ **Reversible**: Early lesions potentially reversible","ğŸ¯ **Irreversible**: Late changes permanent"]},{title:"Triggering Factors",points:["ğŸ¯ **Glucose Administration**: Can precipitate in deficient patients","ğŸ’Š **Medications**: Diuretics, antiemetics","ğŸ”„ **Stress**: Physical or emotional stress","âš¡ **Infections**: Intercurrent infections","ğŸŒŠ **Surgery**: Surgical procedures","ğŸ§¬ **Genetic**: Individual susceptibility"]},{title:"Protective Factors",points:["ğŸ’Š **Early Supplementation**: Prophylactic thiamine","ğŸ½ï¸ **Nutritional Support**: Adequate nutrition","ğŸ’§ **Hydration**: Proper fluid management","âš¡ **Recognition**: Early symptom recognition","ğŸ”„ **Monitoring**: Regular assessment","ğŸ§¬ **Education**: Patient and provider awareness"]}]}],a=()=>[{title:"Causes and Risk Factors for Wernicke's Encephalopathy in Pregnancy",subsections:[{title:"Primary Pregnancy-Related Causes",points:["ğŸ¤¢ **Hyperemesis Gravidarum**: Most common cause (80-90%)","ğŸ’§ **Prolonged Vomiting**: >3 weeks duration","ğŸ½ï¸ **Poor Oral Intake**: Inability to maintain nutrition","âš¡ **Multiple Pregnancies**: Increased metabolic demands","ğŸ”„ **Severe Morning Sickness**: Beyond normal pregnancy nausea","ğŸ¥ **Hospitalization**: For intractable vomiting"]},{title:"Nutritional Risk Factors",points:["ğŸ½ï¸ **Pre-pregnancy Malnutrition**: Poor baseline nutrition","ğŸ§  **Eating Disorders**: Anorexia nervosa, bulimia","ğŸ’° **Food Insecurity**: Limited access to nutritious food","ğŸŒ¾ **Dietary Restrictions**: Extreme dieting, fad diets","âš¡ **Cultural Practices**: Dietary restrictions","ğŸ”„ **Previous Deficiency**: History of vitamin deficiencies"]},{title:"Medical Comorbidities",points:["ğŸ· **Alcohol Use Disorder**: Pre-pregnancy alcohol dependence","ğŸ§  **Psychiatric Disorders**: Depression, anxiety disorders","ğŸ’Š **Medication Use**: Diuretics, antiemetics","âš•ï¸ **Chronic Diseases**: Diabetes, thyroid disorders","ğŸ¦  **Infections**: Severe systemic infections","ğŸ¥ **Previous Surgery**: Bariatric surgery"]},{title:"Gastrointestinal Factors",points:["ğŸ¤¢ **Persistent Nausea**: Beyond first trimester","ğŸ’§ **Malabsorption**: GI disorders affecting absorption","ğŸ”„ **Rapid Transit**: Reduced GI transit time","âš¡ **Medication Effects**: Drugs affecting absorption","ğŸŒŠ **Inflammatory Bowel Disease**: Crohn disease, UC","ğŸ§¬ **Genetic Malabsorption**: Inherited disorders"]},{title:"Precipitating Factors",points:["ğŸ¯ **Glucose Administration**: IV glucose without thiamine","ğŸ’Š **Diuretic Use**: Thiamine losses","âš¡ **Physical Stress**: Surgery, infections","ğŸ”„ **Rapid Refeeding**: Without vitamin supplementation","ğŸŒŠ **Medication Interactions**: Drug-nutrient interactions","ğŸ§  **CNS Infections**: Meningitis, encephalitis"]},{title:"Genetic and Constitutional",points:["ğŸ§¬ **Genetic Polymorphisms**: Transketolase variants","âš¡ **Family History**: Familial susceptibility","ğŸ’« **Ethnic Factors**: Population-specific risks","ğŸ”„ **Individual Variation**: Personal susceptibility","ğŸŒŠ **Metabolic Factors**: Altered thiamine metabolism","ğŸ¯ **Constitutional**: Overall health status"]}]}],o=()=>[{title:"Pathology and Neuropathology of Wernicke's Encephalopathy",subsections:[{title:"Gross Neuropathology",points:["ğŸ§  **Brain Appearance**: Congestion, edema","ğŸ’« **Hemorrhages**: Petechial hemorrhages","âš¡ **Mammillary Bodies**: Discoloration, softening","ğŸ”„ **Thalamus**: Bilateral symmetrical changes","ğŸŒŠ **Periaqueductal**: Gray matter involvement","ğŸ¯ **Brainstem**: Tegmental involvement"]},{title:"Microscopic Changes",points:["ğŸ”¬ **Neuronal Loss**: Selective neuronal death","âš¡ **Gliosis**: Reactive astrocytosis","ğŸ’« **Demyelination**: Loss of myelin sheaths","ğŸ”„ **Capillary Changes**: Endothelial proliferation","ğŸŒŠ **Hemorrhages**: Microhemorrhages","ğŸ§¬ **Inflammation**: Mild inflammatory infiltrate"]}]}],s=()=>[{title:"Classification and Types of Wernicke's Encephalopathy",subsections:[{title:"Clinical Severity",points:["ğŸŸ¢ **Mild**: Subtle cognitive changes","ğŸŸ¡ **Moderate**: Clear neurological signs","ğŸ”´ **Severe**: Coma, major deficits","ğŸš¨ **Fulminant**: Rapid progression"]}]}],r=()=>[{title:"Clinical Presentation of Wernicke's Encephalopathy in Pregnancy",subsections:[{title:"Classic Triad (Uncommon)",points:["ğŸ§  **Mental Confusion**: Altered consciousness, disorientation","ğŸ‘ï¸ **Ophthalmoplegia**: Paralysis of eye movements","ğŸš¶ **Ataxia**: Unsteady gait, poor coordination","ğŸ“Š **Complete Triad**: Present in only 10-16% of cases"]},{title:"Common Pregnancy Presentations",points:["ğŸ˜µ **Altered Mental Status**: Confusion, apathy, stupor","ğŸ¤¢ **Severe Hyperemesis**: Intractable vomiting","ğŸ‘ï¸ **Visual Symptoms**: Diplopia, blurred vision","ğŸš¶ **Balance Problems**: Unsteady walking, falls"]}]}],l=()=>[{title:"Examination Findings in Wernicke's Encephalopathy",subsections:[{title:"Neurological Examination",points:["ğŸ§  **Mental Status**: Confusion, disorientation","ğŸ‘ï¸ **Eye Movements**: Nystagmus, ophthalmoplegia","ğŸš¶ **Gait**: Ataxic gait, wide-based","âš¡ **Reflexes**: Hyperreflexia or hyporeflexia"]}]}],c=()=>[{title:"Investigations for Wernicke's Encephalopathy",subsections:[{title:"Laboratory Tests",points:["ğŸ§ª **Thiamine Levels**: Often normal, unreliable","âš¡ **Transketolase Activity**: Functional assessment","ğŸ’« **Lactate**: May be elevated","ğŸ”„ **Blood Gas**: Metabolic acidosis"]},{title:"Neuroimaging",points:["ğŸ§  **MRI Brain**: T2 hyperintensities in mammillary bodies","âš¡ **FLAIR**: High signal in thalamus","ğŸ’« **DWI**: Restricted diffusion","ğŸ”„ **Contrast**: Enhancement of lesions"]}]}],m=()=>[{title:"Diagnosis of Wernicke's Encephalopathy",subsections:[{title:"Clinical Diagnosis",points:["ğŸ§  **High Suspicion**: Key to diagnosis","ğŸ“Š **Clinical Criteria**: Caine criteria","âš¡ **Response to Treatment**: Improvement with thiamine","ğŸ”„ **Exclusion**: Rule out other causes"]}]}],p=()=>[{title:"Management and Treatment of Wernicke's Encephalopathy",subsections:[{title:"Emergency Treatment",points:["ğŸ’‰ **Immediate Thiamine**: 500mg IV before glucose","âš¡ **High Dose**: Continue 100mg TID for 3 days","ğŸ”„ **IV Route**: Parenteral administration essential","ğŸš¨ **Before Glucose**: Critical to give before dextrose"]}]}],u=()=>[{title:"Prognosis and Outcomes",subsections:[{title:"Recovery Patterns",points:["âš¡ **Early Treatment**: Excellent outcomes","ğŸ§  **Delayed Treatment**: Permanent deficits","ğŸ”„ **Partial Recovery**: Most common pattern","ğŸ“Š **Mortality**: 10-20% if untreated"]}]}],d=()=>[{title:"Kenya-Specific Considerations",subsections:[{title:"Local Factors",points:["ğŸ½ï¸ **Malnutrition**: Higher baseline malnutrition","ğŸ¥ **Healthcare Access**: Limited neurological services","ğŸ’° **Economic Factors**: Cost of treatment","ğŸ“š **Awareness**: Need for increased recognition"]}]}];export{g as getWernickeEncephalopathyContent};
